Trial Profile

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms MAIA
Sponsors Janssen Research & Development; Janssen-Cilag

01 Apr 2025 Results assessing updated efficacy and safety of Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma, published in the Leukemia
20 Dec 2024 Status changed from active, no longer recruiting to completed.
21 Oct 2024 Planned End Date changed from 1 Sep 2024 to 1 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com